Your session is about to expire
← Back to Search
Dose Level 1 - ZH9 for Bladder Cancer (PARADIGM-1 Trial)
PARADIGM-1 Trial Summary
This trial is being conducted to test the safety and effectiveness of a drug called ZH9 in patients with recurrent non-muscle invasive bladder cancer (NMIBC) who can receive treatment directly into the
PARADIGM-1 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPARADIGM-1 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.PARADIGM-1 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are potential participants currently able to apply for enrollment in this trial?
"According to the information provided on clinicaltrials.gov, this particular study is no longer accepting candidates. The trial was originally posted on January 3rd, 2024 and last updated on December 12th, 2023. However, it's worth noting that there are currently 321 other active trials that are actively seeking participants at this time."
Are individuals who are 18 years old or older eligible to participate in this recruitment for the clinical trial?
"Patients between the ages of 18 and 99 are eligible to enroll in this clinical trial. It's worth noting that there are also 12 studies available specifically for individuals under the age of 18, as well as 320 studies targeting patients over the age of 65."
For which individuals is participation in this research study deemed appropriate?
"To be eligible for enrollment in this clinical trial, individuals must have a diagnosis of bladder cancer and fall between the ages of 18 and 99. The study has a maximum capacity to accept 24 participants in total."
Has the Food and Drug Administration (FDA) officially granted approval for Dose Level 3 - ZH9?
"Based on the evaluation conducted by our team at Power, Dose Level 3 - ZH9 is assigned a safety rating of 1. This determination aligns with the early stage of the trial (Phase 1) where available data supporting both safety and efficacy is limited."
Share this study with friends
Copy Link
Messenger